Homologous recombination in prostate cancer

In this production, we’re going to talk about homologous recombination in prostate cancer.

About 14 percent of patients with metastatic castration-resistant prostate carcinoma (mCRPC) have a BRCA1/2 mutation. Mutations in other genes related to homologous recombination deficiency (HRD) can also occur in prostate cancer. We know that a total of ~30% of patients have such HRR-mutations. These mutations are important for the use of PARP inhibitors, as well as for the prognosis of the disease. However, little is known about the influence of individual HRR genes.

Research shows how common HRR mutations are and what effects they have on the disease and treatment.

We asked two physicians to interact, a Dutch prostate cancer expert and an international HRR/prostate cancer expert. They discuss the clinical implications of HRR-mutations in metastatic prostate cancer. Which genes are being looked at, what do these mutations imply and what is the impact on treatment? 

Experts

• Elena Castro, medical oncologist, Hospital Universitario 12 de Octubre, Madrid
• Addy van de Luijtgaarden, medical oncologist, Reinier de Graaf Gasthuis, Delft